In the final part of his conversation with Pharmaceutical Executive, Clay Siegall (president and CEO of Immunome) details the next steps for his upcoming medication.
Clay Siegall
Advertisement
Articles by Clay Siegall
Immunome president and CEO Clay Siegall explains why the weeks following JP Morgan are just as important as the conference itself.
Clay Siegall, president and CEO of Immunome, discusses what he saw investors getting excited for at the annual healthcare conference.
Advertisement